In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of the combination of nivolumab and ipilimumab in patients with aggressive thyroid carcinoma.
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential of incretin mimetics to reduce breast cancer risk, particularly in…
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson…
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
The call for late-breaking abstracts for the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer is now open! The deadline for submissions…
The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
Discover the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and more. Listen today
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
